Business Context and Reporting Period
CalciMedica, Inc. (CALC) filed a Form 8-K on June 23, 2026, reporting the entry into material definitive agreements with Avenue Venture Opportunities Fund II, L.P. and Avenue Capital Management II, L.P. The filing details amendments to an existing Loan and Security Agreement dated February 28, 2025, and the issuance of new and amended warrants.
Key Financial Metrics and Debt Structure
- Outstanding Principal: $10,000,000 under the amended Loan Agreement.
- Interest-Only Period: Extended from September 30, 2026, to September 30, 2027.
- Amortization Commencement: Delayed to October 1, 2027.
- Maturity Date: Extended from September 1, 2028, to September 1, 2029.
- Final Payment Fee: Increased by $200,000 payable upon maturity or full prepayment.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these operational metrics.
Material Changes Versus Prior Period
The filing outlines significant modifications to the Company's debt and equity instruments compared to the original February 2025 agreements:
- Debt Extension: The maturity date was pushed back by one year, and the interest-only period was extended by one year, deferring principal amortization.
- Conversion Rights Expansion: The Lender's right to convert principal into common stock was increased from $1,000,000 to up to $3,000,000. The Lender may now choose between common stock or pre-funded warrants.
- Put Option Grant: The Company received a new option to force the Lender to convert up to 20% of the average daily trading volume if the stock price exceeds the conversion price by 50%.
- Warrant Price Reduction: The exercise price for the original warrant (641,163 shares) was reduced from $2.32 to $1.00.
- New Warrant Issuance: A new warrant for 1,000,000 shares was issued with an exercise price of $1.00, expiring June 23, 2031.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking financial guidance or management commentary regarding future operational performance. Key risks and contingencies identified include:
- Dilution Risk: The expansion of conversion rights and the issuance of new warrants at a $1.00 exercise price create potential dilution for existing shareholders.
- Beneficial Ownership Limitations: Both the conversion option and warrant exercises are subject to a 19.99% beneficial ownership cap. If this limit is reached, conversions must be made via pre-funded warrants rather than common stock.
- Unregistered Securities: The conversion securities and new warrants were sold under Section 4(a)(2) of the Securities Act and are not registered.
- Change of Control: The new warrant includes a provision where the Lender receives underlying shares without payment of the exercise price upon a change of control.
Investor Verification Checklist
- Verify the total potential dilution impact of the $3,000,000 conversion option and the 1,641,163 total warrant shares at the $1.00 exercise price.
- Confirm the Company's current cash runway given the extension of the interest-only period to late 2027.
- Review the full text of the Loan First Amendment (Exhibit 10.1) for any covenants or default triggers not summarized in the 8-K.
- Monitor the stock price relative to the $1.00 conversion/exercise price to assess the likelihood of the Lender exercising the Put Option or conversion rights.